Pharma BD Deal Intelligence
Amgen to acquire Micromet, adding blinatumomab and the BiTE bispecific antibody platform to its oncology pipeline through a tender offer at $11 per share.
Micromet board recommends the $11.00 per share all-cash tender offer from Amgen, representing a premium for shareholders and providing resources to advance the…
FDA granted accelerated approval to blinatumomab in December 2014 for Ph-negative R/R B-ALL, less than three years after Amgen's $1.16B acquisition of…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Amgen tender offer at $11/share cash for Micromet, valuing the company at approximately $1.16B. Acquisition delivered the BiTE bispecific antibody platform and lead asset blinatumomab in Phase 2 for relapsed/refractory ALL.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Micromet Inc. (this deal) | 2012 | $1.2B | 88 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2012 deals · Amgen Inc. deals · Hematology deals